newsfilter
← Latest News
GlobeNewswire·

AIM ImmunoTech Provides Update on Ampligen Long COVID Development Program

OCALA, Fla., May 18, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AMERICAN) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and vira